Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J U Gutterman

Showing results (171-180 of 333) with videos related to

Pageof 34
Sort By:
Lancet (London, England)|June 2, 1973
Active immunotherapy with B.C.G. for recurrent malignant melanomaJ U Gutterman, G Mavligit, C McBride, et al.
Oncogene|February 16, 1999
Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202D H Yan, Y Wen, B Spohn, et al.
Seminars in Oncology|June 1, 1975
Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the futureJ U Gutterman, G Mavligit, R Reed, et al.
Leukemia|March 1, 1991
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progressionK Dhingra, M Talpaz, H Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1990
Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastasesG M Mavligit, A A Zukiwski, J U Gutterman, et al.
Journal of Biological Response Modifiers|April 1, 1988
Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigensJ L Murray, S E Stuckey, J K Pillow, et al.
Immunological Communications|January 1, 1974
Immunoglobulins on the surface of human appendix lymphocytesA V Jubert, C M Mc Bride, G Mavligit, et al.
Cancer Treatment Reports|May 1, 1976
Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized studyS P Richman, R B Livingston, J U Gutterman, et al.
Cancer Chemotherapy Reports|November 1, 1973
Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical studyR W Talley, R M O'Bryan, J U Gutterman, et al.
Cancer Treatment Reports|May 1, 1977
Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-GuérinS P Richman, J U Gutterman, E M Hersh, et al.
Pageof 34

Showing results (171-180 of 333) with videos related to

Sort By:
Pageof 34
Lancet (London, England)|June 2, 1973
Active immunotherapy with B.C.G. for recurrent malignant melanomaJ U Gutterman, G Mavligit, C McBride, et al.
Oncogene|February 16, 1999
Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202D H Yan, Y Wen, B Spohn, et al.
Seminars in Oncology|June 1, 1975
Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the futureJ U Gutterman, G Mavligit, R Reed, et al.
Leukemia|March 1, 1991
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progressionK Dhingra, M Talpaz, H Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1990
Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastasesG M Mavligit, A A Zukiwski, J U Gutterman, et al.
Journal of Biological Response Modifiers|April 1, 1988
Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigensJ L Murray, S E Stuckey, J K Pillow, et al.
Immunological Communications|January 1, 1974
Immunoglobulins on the surface of human appendix lymphocytesA V Jubert, C M Mc Bride, G Mavligit, et al.
Cancer Treatment Reports|May 1, 1976
Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized studyS P Richman, R B Livingston, J U Gutterman, et al.
Cancer Chemotherapy Reports|November 1, 1973
Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical studyR W Talley, R M O'Bryan, J U Gutterman, et al.
Cancer Treatment Reports|May 1, 1977
Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-GuérinS P Richman, J U Gutterman, E M Hersh, et al.
Pageof 34